121
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Efficacy of Low-Dose Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jirovecii Pneumonia in Deceased Donor Kidney Recipients

, , , , , , , , & show all
Pages 4913-4920 | Published online: 24 Nov 2021

References

  • Struijk GH, Gijsen AF, Yong SL, et al. Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation. Nephrol Dial Transplant. 2011;26(10):3391–3398. doi:10.1093/ndt/gfr04821385859
  • Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17(4):770–782, table of contents. doi:10.1128/cmr.17.4.770-782.200415489347
  • Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation. 2009;88(1):135–141. doi:10.1097/TP.0b013e3181aad25619584693
  • Eitner F, Hauser IA, Rettkowski O, et al. Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant. 2011;26(6):2013–2017. doi:10.1093/ndt/gfq68921071545
  • Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350(24):2487–2498. doi:10.1056/NEJMra03258815190141
  • Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;2014(10):Cd005590. doi:10.1002/14651858.CD005590.pub3
  • European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.7.1 late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant. 2002;17(Suppl 4):36–39. doi:10.1093/ndt/17.suppl_4.36-a12091642
  • Goto N, Futamura K, Okada M, et al. Management of Pneumocystis jirovecii pneumonia in kidney transplantation to prevent further outbreak. Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):81–90. doi:10.4137/ccrpm.s2331726609250
  • Li T, Shi J, Xu F, Xu X. Clinical characteristics of pneumocystis pneumonia after parental renal transplantation. Infect Drug Resist. 2020;13:81–88. doi:10.2147/idr.s23403932021322
  • Tu GW, Ju MJ, Xu M, et al. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients. Nephrology (Carlton). 2013;18(11):736–742. doi:10.1111/nep.1213324571744
  • Chai YX, Ji JL, Li SJ, et al. Efficacy of anti-T-lymphocyte globulin-Fresenius as an induction agent in deceased-donor renal transplantation: a cohort study. Exp Ther Med. 2020;19(3):2384–2390. doi:10.3892/etm.2020.845132104307
  • Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77(4):299–311. doi:10.1038/ki.2009.37719847156
  • Chadban SJ, Barraclough KA, Campbell SB, et al. KHA-CARI guideline: KHA-CARI adaptation of the KDIGO clinical practice guideline for the care of kidney transplant recipients. Nephrology (Carlton). 2012;17(3):204–214. doi:10.1111/j.1440-1797.2011.01559.x22212251
  • Borstnar S, Lindic J, Tomazic J, et al. Pneumocystis jirovecii pneumonia in renal transplant recipients: a national center experience. Transplant Proc. 2013;45(4):1614–1617. doi:10.1016/j.transproceed.2013.02.10723726632
  • Costa JM, Botterel F, Cabaret O, Foulet F, Cordonnier C, Bretagne S. Association between circulating DNA, serum (1->3)-β-D-glucan, and pulmonary fungal burden in Pneumocystis pneumonia. Clin Infect Dis. 2012;55(2):e5–8. doi:10.1093/cid/cis41222523258
  • Corsi-Vasquez G, Ostrosky-Zeichner L, Pilkington EF, Sax PE, Caliendo AM. Point-counterpoint: should serum β-d glucan testing be used for the diagnosis of Pneumocystis jirovecii pneumonia? J Clin Microbiol. 2019;58(1). doi:10.1128/jcm.01340-19
  • de Boer MG, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis. 2011;13(6):559–569. doi:10.1111/j.1399-3062.2011.00645.x21689251
  • Muhammad Iqbal AH, Lim SK, Ng KP, Tan LP, Chong YB, Keng TC. Pneumocystis jirovecii pneumonia 13 years post renal transplant following a recurrent cytomegalovirus infection. Transpl Infect Dis. 2012;14(4):E23–E26. doi:10.1111/j.1399-3062.2012.00738.x22551151
  • Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):272–279. doi:10.1111/ajt.1211923465020
  • White PL, Price JS, Backx M. Therapy and management of Pneumocystis jirovecii infection. J Fungi (Basel). 2018;4(4). doi:10.3390/jof4040127
  • Thomas M, Rupali P, Woodhouse A, Ellis-Pegler R. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients. Scand J Infect Dis. 2009;41(11–12):862–868. doi:10.3109/0036554090321425619922070
  • Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transplant. 2012;26(3):E184–190. doi:10.1111/j.1399-0012.2012.01624.x22487221
  • Giullian JA, Cavanaugh K, Schaefer H. Lower risk of urinary tract infection with low-dose trimethoprim/sulfamethoxazole compared to dapsone prophylaxis in older renal transplant patients on a rapid steroid-withdrawal immunosuppression regimen. Clin Transplant. 2010;24(5):636–642. doi:10.1111/j.1399-0012.2009.01129.x19925478
  • Mitsides N, Greenan K, Green D, et al. Complications and outcomes of trimethoprim-sulphamethoxazole as chemoprophylaxis for pneumocystis pneumonia in renal transplant recipients. Nephrology (Carlton). 2014;19(3):157–163. doi:10.1111/nep.1220124387294
  • Aliouat-Denis CM, Martinez A, Aliouat El M, Pottier M, Gantois N, Dei-Cas E. The Pneumocystis life cycle. Mem Inst Oswaldo Cruz. 2009;104(3):419–426. doi:10.1590/s0074-0276200900030000419547866
  • Dei-Cas E. Pneumocystis infections: the iceberg? Med Mycol. 2000;38(Suppl 1):23–32. doi:10.1080/mmy.38.s1.23.32
  • Armstrong-James D, Stebbing J, John L, et al. A trial of caspofungin salvage treatment in PCP pneumonia. Thorax. 2011;66(6):537–538. doi:10.1136/thx.2010.135350
  • Koshy R, Chen T. Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia. IDCases. 2019;15:e00496. doi:10.1016/j.idcr.2019.e0049630828545
  • Kasiske B, Zeier M, Craig J, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–155. doi:10.1111/j.1600-6143.2009.02834.x